PuMP: Oncolytic HSV1 MVR-C5252 in Patients with rHGG (Recurrent Glioma)

Purpose of this Study

We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.

Who Can Participate?

Eligibility

Adults ages 18+ who are diagnosed with recurrent high-grade glioma. For more information about this study, please call 919-668-3726.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you join the study, you will:
  • Have a physical and neurological exam and other tests
  • Have magnetic resonance imaging (MRI) of the brain
  • Have blood draws
  • Have brain tumor biopsy and testing of tumor sample
  • Have a catheter (small flexible tube) placed in and around the tumor with the other end of the catheter extending slightly outside of the head
  • Get the study drug infused through an external pump and the implanted catheter

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

The PuMP Trial: A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients with Recurrent High-Grade Glioma

Principal Investigator

Mustafa
Khasraw

Protocol Number

PRO00112883

NCT ID

NCT06126744

Phase

I

Enrollment Status

Open to Enrollment